Latest Biotech News

The FDA rejected Replimune’s oncolytic virus therapy for advanced melanoma again, citing unresolved doubts about the study results after the company’s resubmission. The latest action extends a...

Oricell Therapeutics closed a pre-IPO funding round raising more than $110 million, aiming to expand its global footprint and advance a GPC3-targeted autologous CAR-T for liver cancer toward...

In immune thrombocytopenia (ITP), a Phase 2 trial reported that mezagitamab materially increased platelet counts, providing a fresh clinical read-through for antibody-based options in a space...

The FDA accepted Telix Pharmaceuticals’ resubmitted NDA for TLX101-Px (Pixclara), a radiolabeled imaging agent for characterizing progressive or recurrent glioma across adult and pediatric...

Gilead Sciences exercised its option to exclusively license Kymera Therapeutics’ KT-200, an oral CDK2 molecular glue degrader candidate. The move follows a strategic collaboration in which Gilead...

Stipple Bio raised a $100 million Series A after emerging from stealth, targeting improved therapeutic windows in antibody-drug conjugates (ADCs) by engineering tumor-specific binders through...

Realta Life Sciences secured an additional $40 million in the final tranche of its Series A funding for its hypoxic ischemic encephalopathy (HIE) treatment. The round brings Realta’s total raised...

Oricell’s pre-IPO fundraising continued to draw attention as the company moved closer to potential capital-market milestones while scaling its solid-tumor CAR-T platform. Separate deal coverage...

FairJourney Bio opened an advanced cryo-electron microscopy (cryo-EM) structural biology facility in San Diego, expanding its U.S. footprint and integrating atomic-resolution structural biology...

Swan Genomics, a startup developing optical nanoantenna-based single-molecule sequencing, raised A$8 million (about $5.8 million) in seed funding to advance proof of concept and pursue a Series A....

The FDA rejected Replimune’s oncolytic virus therapy (RP-1) for advanced melanoma for a second time, according to multiple reports tied to recent PDUFA and resubmission dates. The agency said...

Oricell Therapeutics closed a $110 million pre-IPO financing to broaden its pipeline of solid-tumor cell therapies, with a focus on its GPC3-targeted autologous CAR-T program for hepatocellular...

The U.S. FDA accepted Telix Pharmaceuticals’ resubmitted NDA for TLX101-Px (Pixclara), a radiolabeled imaging agent intended to characterize progressive or recurrent glioma in both adults and...

Researchers reported a strategy to optimize CAR T-cell therapy by precisely modulating receptor affinity, aiming to balance antitumor efficacy with safety. The work frames receptor affinity as a...

Replimune-free? No—separate development: a Phase 2 trial report indicates mezagitamab, an investigational antibody for immune thrombocytopenia (ITP), significantly increased platelet counts in...

Agilent highlighted how lab automation can scale characterization workflows for antibody-drug conjugates (ADCs) and other targeted biologics, focusing on faster, more reproducible development....

FairJourney Bio opened a new cryo-electron microscopy (cryo-EM) structural biology facility in San Diego, expanding its U.S. footprint and integrating atomic-resolution structure capabilities into...

Eli Lilly launched its oral obesity pill Foundayo, entering direct competition with Novo Nordisk’s oral Wegovy and intensifying the pricing-and-access push in the rapidly expanding GLP-1 category....

Chapter raised $100 million in a Series E round to address “Medicare mismatches” affecting seniors, according to a report describing the company’s funding and investor participation. The financing...

Realta Life Sciences raised an additional $40 million in the final tranche of its Series A round, bringing total funding to more than $150 million. The company’s program targets hypoxic ischemic...